Lina Irawan
As global geopolitical shifts and economic volatility continue to reshape the international healthcare landscape, the Committee representing leading pharmaceutical stakeholders has issued a comprehensive set of recommendations aimed at bolstering Taiwan’s healthcare infrastructure. The proposal focuses on three primary pillars: enhancing supply chain resilience, ensuring the long-term sustainability of the National Health Insurance (NHI) system, and elevating Taiwan’s standing as a competitive hub for global biotechnology and pharmaceutical innovation. At the heart of these recommendations is the recognition that Taiwan’s current drug pricing and reimbursement structures must evolve to keep pace with international standards and to ensure that Taiwanese patients maintain timely access to life-saving innovative therapies.
The Committee’s advocacy comes at a pivotal moment in Taiwan’s domestic policy evolution. With the administration of President Lai Ching-te prioritizing the Healthy Taiwan initiative and identifying biotechnology as one of the Five Trusted Industries, the pharmaceutical sector is increasingly viewed as a cornerstone of national security and economic growth. However, the Committee warns that without a more predictable regulatory environment and a pricing framework that reflects the true value of innovation, Taiwan risks falling behind in the global race for new drug launches and clinical trial investments.
Establishing a Framework for Strategic International Dialogue
One of the central tenets of the Committee’s proposal is the establishment of a regularized, high-level policy dialogue mechanism between the United States and Taiwan. This recommendation builds upon recent diplomatic successes, most notably the breakthrough in addressing U.S. tariff measures that granted duty-free treatment to Taiwanese generic drugs and active pharmaceutical ingredients (APIs). To capitalize on this momentum, the Committee urges the formalization of a U.S.-Taiwan pharmaceutical policy dialogue that would institutionalize exchanges between government officials, industry leaders, and academic experts.
Such a platform would serve as a critical venue for discussing regulatory alignment, pharmaceutical pricing trends, and the introduction of innovative medicines. To support the effectiveness of this dialogue, the Committee suggests that the National Health Insurance Administration (NHIA) conduct biannual consultations with industry stakeholders. This proactive approach would allow for a joint review of global economic trends, ensuring that Taiwan’s healthcare policies remain responsive to international market dynamics. Furthermore, the Committee proposes leveraging the Global Cooperation and Training Framework (GCTF) to showcase Taiwan’s healthcare governance strengths on the world stage, fostering deeper collaboration with global partners beyond the bilateral U.S.-Taiwan relationship.
Aligning Reimbursement with International Clinical Standards
A significant portion of the Committee’s report addresses the disparities between Taiwan’s NHI reimbursement conditions and international treatment guidelines. While the government has received praise for its Healthy Taiwan vision—particularly its focus on improving cancer care through the creation of a dedicated Cancer Drugs Fund—the Committee notes that significant gaps remain for non-cancer medicines and certain specialized oncology therapies.
Current restrictions often limit the eligible patient population, impose strict requirements on prior lines of treatment, or constrain dosing and treatment duration in ways that deviate from global best practices. These misalignments create a dual challenge: they prevent physicians from providing the highest standard of care and discourage multinational pharmaceutical companies from including Taiwan in global clinical trials. By accelerating the alignment of reimbursement conditions with international guidelines across all disease areas, the Committee argues that Taiwan can enhance its "clinical value positioning," making the domestic healthcare system more attractive for international research and development (R&D) collaborations.
Ensuring Financial Sustainability through Evidence-Based Funding
The introduction of innovative medicines is a primary driver of healthcare quality, but it requires a sustainable funding model. The Committee welcomes the government’s commitment to establish a NT$10 billion Cancer Drugs Fund by 2025, yet it emphasizes that the long-term viability of such initiatives depends on a more sophisticated budgeting approach. Rather than relying on static data indicators, the Committee recommends a medium-to-long-term outlook that incorporates "horizon scanning"—a methodology used to anticipate future medical breakthroughs and assess their potential impact on the healthcare budget.
This holistic assessment would enable the government to allocate resources more precisely, ensuring that policy directions achieve intended health outcomes without interrupting patient access. Additionally, the Committee highlights the importance of maintaining pricing premiums for drugs supported by domestic clinical trials. Such incentives are vital for attracting multinational investment in Taiwan’s R&D ecosystem, ultimately allowing local patients to benefit from globally innovative therapies much earlier in the product lifecycle.
Reforming Drug Pricing to Maintain Launch Advantages
In the current global economic climate, pharmaceutical headquarters are increasingly scrutinizing national pricing structures when deciding where to launch new products. If a market’s prices are excessively low, it can trigger a "race to the bottom" in other regions due to international reference pricing systems. The Committee warns that if Taiwan’s pricing remains overly compressed, the island may be deprioritized in global launch strategies.
To mitigate this risk, the Committee recommends a comprehensive review of the NHI Pharmaceutical Reimbursement and Payment Standards. Key suggestions include:
- Adopting a pricing model based on the median of 10 reference countries.
- Implementing value-based price adjustments that reflect clinical safety, effectiveness, and convenience.
- Providing specific incentives for pediatric medications and pharmacoeconomic studies conducted within Taiwan.
- Establishing clear pricing premiums for therapies addressing urgent unmet medical needs or for companies that establish manufacturing bases in Taiwan.
These measures are designed to reinforce Taiwan’s position as a "trusted pharmaceutical supply chain hub" in the Asia-Pacific region, ensuring that the market remains competitive and attractive to global investors.
Enhancing Predictability in Reimbursement Agreements
Pharmaceutical Reimbursement Agreements (PRAs) have become a crucial tool for the NHIA to manage the budget while providing access to high-cost innovative drugs. However, the Committee points out that current implementation often prioritizes short-term financial controls, such as high rebate requirements and hard spending caps. This can lead to a lack of transparency and predictability for manufacturers.
The Committee advocates for a PRA framework characterized by procedural fairness and reasonable risk-sharing. Specifically, they call for simplified procedures, the avoidance of overly complex multi-layered agreements, and the assurance of strict confidentiality regarding agreement terms. By fostering a more balanced negotiation environment, Taiwan can encourage multinational companies to prioritize the Taiwanese market for their most advanced therapeutic innovations.
Managing the Drug Lifecycle and Intellectual Property Rights
A robust pharmaceutical ecosystem requires a lifecycle management system that respects intellectual property (IP) and ensures fair price adjustments. The Committee expressed concerns regarding the current "patent expiry rule," which sometimes leads to price reductions for innovative medicines that still hold valid patents in Taiwan. This practice is seen as inconsistent with international patent protections and can undermine the value of innovation.
Furthermore, the Committee addressed the Drug Expenditure Target (DET) system. While intended to control spending, the baseline values for DET calculations have not been updated in over a decade, leading to distorted pricing signals and potential supply instabilities. The Committee urges the NHIA to recalibrate these baselines in consultation with industry stakeholders to ensure that price adjustments do not compromise drug supply resilience.
Strengthening Supply Resilience through Legislative Action
The recent amendment to Article 27 of the Pharmaceutical Affairs Act marks a significant shift from reactive shortage management to proactive risk mitigation. The Committee commends this move but cautions that the subsequent regulations must be carefully calibrated to avoid imposing excessive administrative burdens on the industry.
The recommendations suggest a risk-based approach to supply reporting and inventory management. For example, products with a history of stable supply should not be subject to the same level of rigorous reporting as those at higher risk of shortage. Additionally, the Committee emphasizes that forecast data provided by companies should be used for monitoring purposes only, rather than as a basis for punitive measures. This collaborative approach between the government and the private sector is essential for building a truly resilient drug supply chain.
Conclusion: A Vision for a Healthy and Competitive Taiwan
The recommendations provided by the Committee serve as a roadmap for integrating Taiwan more deeply into the global pharmaceutical value chain. By formalizing international dialogues, aligning with global clinical standards, and reforming pricing and reimbursement mechanisms, Taiwan can transform its healthcare system into a powerful engine for both public health and economic prosperity.
The Committee’s call for deeper public-private collaboration underscores the reality that healthcare resilience is not merely a budgetary concern but a strategic national interest. As the Lai administration moves forward with its "Five Trusted Industries" and "Healthy Taiwan" agendas, the implementation of these pharmaceutical policy reforms will be a critical litmus test for Taiwan’s ability to maintain its competitive edge in an increasingly complex global environment. Through transparency, predictability, and a commitment to innovation, Taiwan can ensure that its citizens continue to receive world-class medical care while the nation cements its role as a leader in the global life sciences sector.
Layla Zulfa
Jia Lissa
